Clinical Trial Search

Primary: Overall Response Rate — 11 Participants

Primary: Progression-free Survival to Determine the 6-month Progression-free-survival (PFS) Rate — 5.4 months

Primary: PET-CT Fusion Scanning Sensitivity — 49; 54 percentage of participants

Primary: Response at 6 Months — 7; 2 Participants — p=0.0787

Primary: Increased Radioiodine Uptake — 6 Participants

Primary: Tumor Major Response Rate (Including Stable Disease) as Measured by RECIST Criteria — 10; 1 participants

Primary: Percentage of Participants With Objective Response (OR) — 38.3 Percentage of participants

Primary: Calcitonin Growth Rate — -2.53; -2.49 days^-1 — p=0.3760

Primary: Median Progression Free Survival — 12.5 months

Primary: Objective Response Rate of Sorafenib Tosylate in Metastatic Medullary Thyroid Carcinoma in Setting of Inherited Tumor Syndromes as Well as in Setting of Sporadic…

Primary: Clinical Response — 0; 0 Participants

Primary: Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration — 0 participants

Primary: Progression Free Survival — 241 days

Primary: Percentage of Participants With Transient Hypoparathyroidism, as Defined by a Day 1 Serum Parathyroid Hormone (PTH) Level of < 10 pg/ml — 24.1; 33.3 percentage of…

Primary: Changes in Thyroid Nodule Size — 0.241361; 0.954909; 0.422121; 0.104143 mL

Primary: Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation — 329; 175 Days — p=<0.0001

Primary: Percentage of Participants With Objective Response (OR) — 34.6 percentage of participants

Primary: Number of Participants With Response Per Responsive Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) — 17; 9; 11 Participants

Primary: Objective Response Rate, Defined as the Proportion of Patients Who Have Had a PR or CR as Assessed by the RECIST Version (v)1.1 — 10 Participants

Primary: Objective Tumor Response Rate Assessed by RECIST — 0 participants

Primary: Number of Patients Whose Tumor(s) Acquire an Increased Propensity for Iodine Uptake as Detected on Iodine-124 Positron Emission Tomography Scan — 12; 8 participants

Primary: Objective Response Rate, Assessed Using the Response Evaluation Criteria in Solid Tumors (RECIST) — 9; 7 Participants — p=<0.10

Primary: To Determine the Efficacy (Best Response) of BAY 43-9006 (Objective Response Rate and Stable Disease) in Patients With Metastatic Thyroid Carcinoma. — 0; 16; 22; 1…

Primary: Response Rate — 17 Participants

Primary: Objective Response Rate — 6 Participants

Primary: Change in Tumor Size — 4.7 cm

Primary: Overall Objective Response Rate, Defined as the Proportion of Patients Who Have a Minor Response (MR), Partial Response (PR), or Complete Response(CR)Assessed According…

Primary: Primary Efficacy Parameters of Sensitivity of High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles (LSN MRI) — 85.5 percentage…

Primary: Objective Tumor Response Rate at 3, 6, and 12 Months — 0; 0; 12; 13 participants

Primary: Time to Tumor Progression — 334; 176 days